

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

POSTPONEMENT OF BOARD MEETING

The board of directors (the “**Board**”) of PuraPharm Corporation Limited (the “**Company**”) refers to the announcement issued by the Company dated 13 March 2024 in relation to the convening of a meeting of the Board (the “**Board Meeting**”) on Monday, 25 March 2024 for the purposes of, among others, considering and approving the annual results of the Company and its subsidiaries for the year ended 31 December 2023 (the “**Annual Results**”) and its publication, and considering the payment of a final dividend, if any.

The Board hereby announces that as the Company requires additional time to finalize the Annual Results, the aforesaid board meeting will be postponed to Thursday, 28 March 2024.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 22 March 2024

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.